AtaiBeckley Inc. (ATAI)
| Market Cap | 1.48B +383.7% |
| Revenue (ttm) | 4.09M +1,227.6% |
| Net Income | -660.05M |
| EPS | -2.91 |
| Shares Out | 366.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,860,116 |
| Open | 4.030 |
| Previous Close | 4.010 |
| Day's Range | 3.945 - 4.075 |
| 52-Week Range | 1.290 - 6.750 |
| Beta | 1.60 |
| Analysts | Strong Buy |
| Price Target | 15.88 (+294.05%) |
| Earnings Date | May 11, 2026 |
About ATAI
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophr... [Read more]
Financial Performance
In 2025, AtaiBeckley's revenue was $4.09 million, an increase of 1227.60% compared to the previous year's $308,000. Losses were -$660.05 million, 342.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for ATAI stock is "Strong Buy." The 12-month stock price target is $15.88, which is an increase of 294.05% from the latest price.
News
Analysts see 200%+ upside in these 3 high-risk stocks: here's why?
Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in small, volatile stocks with thin balance sheets, limited operating history and one big event ahead.
AtaiBeckley Transcript: Needham Virtual Psychedelics Forum
Psychedelic drug development is accelerating due to regulatory support and political momentum, with late-stage trials underway and commercial readiness targeted for year-end. Companies are addressing clinical, operational, and payer challenges, leveraging expanded infrastructure and new reimbursement models to drive adoption.
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developi...
AtaiBeckley Announces Additional Phase 2a Results for EMP-01 (oral R-MDMA) Showing Large and Consistent Improvements in Social Anxiety Disorder
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developi...
How Trump's psychedelics executive order could unlock stalled cannabis reform
The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine. The order does not change their legal status,...
Psychedelic Stocks Surge After Trump Signs Order Fast-Tracking Drug Research
The only drug named in Trump's executive order is ibogaine, a psychedelic commonly used to treat depression, anxiety and PTSD among veterans. The drug, a Schedule I substance banned in the U.S., has b...
AtaiBeckley price target raised to $15 from $14 at Canaccord
Canaccord analyst Sumant Kulkarni raised the firm’s price target on AtaiBeckley (ATAI) to $15 from $14 and keeps a Buy rating on the shares. The firm updated its model following
Psychedelic stocks rally with Trump's support
An executive order aims to speed up how quickly psychedelic drugs for mental illness can move through the regulatory process.
Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring.
AtaiBeckley and Compass Pathways are two drugmakers developing psychedelic treatments for depression.
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
Shares of psychedelic drug developers rose in premarket trading on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews of psychedelic dr...
AtaiBeckley price target raised to $16 from $11 at Guggenheim
Guggenheim raised the firm’s price target on AtaiBeckley (ATAI) to $16 from $11 and keeps a Buy rating on the shares. The firm’s recent meetings with management reinforced its “conviction”
AtaiBeckley Transcript: 25th Annual Needham Virtual Healthcare Conference
Late-stage clinical programs focus on short-duration psychedelic therapies for mental health, with BPL-003 entering phase III for TRD and promising phase II data showing rapid, durable effects. Market strategy targets integration into existing Spravato clinics, and top-line phase III results are expected in Q1 2029.
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences
Dr. Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, will participate in the 25th Annual Needham Virtual Healthcare Conference (April 13 - 16) and the Needham Virtual Psychedelics ...
Psychedelic: AtaiBeckley reports publication of BPL-003 study results
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a publication of study results, a clinical site network expansion and a
AtaiBeckley announces peer-reviewed Phase 2a results of BPL-003 study
AtaiBeckley (ATAI) announced peer-reviewed Phase 2a results in CNS Drugs demonstrating that a single intranasal dose of BPL-003, or mebufotenin benzoate, which holds FDA Breakthrough Therapy Designati...
AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developi...
AtaiBeckley initiated with a Buy at Deutsche Bank
Deutsche Bank last night initiated coverage of AtaiBeckley (ATAI) with a Buy rating and $12 price target The company is well positioned for the psychedelic “renaissance,” the analyst tells investors
AtaiBeckley initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of AtaiBeckley (ATAI) with a Buy rating and $12 price target
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
Inclusion in U.S. CRSP® benchmark indices triggers mandatory position-building by passive index funds tracking more than $3 trillion in AUM, including the world's largest mutual fund Expands market pr...
Psychedelic: AtaiBeckley reports publication of BPL-003 study results
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a publication of study results, confirmation of an NDA path and continued
AtaiBeckley Transcript: Leerink Global Healthcare Conference 2026
Three advanced assets for mental health—BPL-003, VLS-01, and EMP-01—show strong efficacy and short treatment durations, aligning with the SPRAVATO clinic model. Regulatory-aligned trials and robust infrastructure position these therapies for broad adoption in interventional psychiatry.
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developi...
AtaiBeckley Transcript: Investor Day 2026
The event outlined a strategy focused on rapid, durable, and scalable psychedelic therapies for TRD and SAD, with BPL-003 advancing to phase III after strong phase IIb results. The product’s short in-clinic time, robust IP, and seamless fit with existing infrastructure position it for broad adoption and premium pricing.
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by deve...
AtaiBeckley Transcript: TD Cowen 46th Annual Health Care Conference
Two pivotal Phase III trials for BPL-003 in TRD are underway, featuring single and double dosing regimens with placebo controls and enhanced safety monitoring. Phase IIb data support the 8 mg dose for efficacy and tolerability. EMP-01 in social anxiety disorder showed rapid, SSRI-comparable behavioral improvements, with further analyses expected soon.